|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
tricin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] |
CTD |
PMID:16552572 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
3',5'-dimethoxyflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:12644593 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
chrysoeriol results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene binds to AHR protein] |
CTD |
PMID:20553787 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BGLAP protein] |
CTD |
PMID:20981859 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein] |
CTD |
PMID:20981859 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mtnr1a |
melatonin receptor 1A |
affects binding |
ISO |
chrysoeriol binds to MTNR1A protein |
CTD |
PMID:20399199 |
|
NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919
|
|
G |
Mtnr1b |
melatonin receptor 1B |
affects binding |
ISO |
chrysoeriol binds to MTNR1B protein |
CTD |
PMID:20399199 |
|
NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] |
CTD |
PMID:20399199 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFSF11 protein] |
CTD |
PMID:20981859 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
ISO |
[CYP1A1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin CYP1A1 protein results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases chemical synthesis multiple interactions |
ISO |
CYP1B1 protein results in increased chemical synthesis of 6-hydroxyluteolin [CYP1B1 protein affects the metabolism of scutellarein] which results in increased chemical synthesis of 6-hydroxyluteolin |
CTD |
PMID:19666078 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of ACP5 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form] |
CTD |
PMID:35191607 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases response to substance multiple interactions |
ISO |
diosmetin results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased susceptibility to diosmetin [CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin |
CTD |
PMID:10781868 PMID:21482471 PMID:33727136 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity multiple interactions increases response to substance |
ISO |
diosmetin results in decreased activity of CYP1A2 protein [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin CYP1A2 protein results in increased susceptibility to diosmetin |
CTD |
PMID:28867436 PMID:33727136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C8 protein |
CTD |
PMID:28867436 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2E1 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of HMOX1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL18 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:35191607 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL1B protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein] |
CTD |
PMID:35191607 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of KEAP1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36563736 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:36563736 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36563736 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36563736 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of NFATC1 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NFE2L2 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16934226 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NLRP3 protein] |
CTD |
PMID:35191607 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NQO1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
diosmetin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PYCARD protein] |
CTD |
PMID:35191607 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[diosmetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:28867436 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16934226 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of ENO2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of and results in decreased activity of GPX1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] |
CTD |
PMID:32061149 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:29187079 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGER2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:29187079 PMID:32061149 PMID:35920545 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:32061149 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases response to substance increases metabolic processing decreases activity increases expression |
ISO |
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18454852 PMID:19601638 PMID:21482471 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing increases expression decreases activity |
ISO |
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2C19 protein |
CTD |
PMID:21093571 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2D6 protein |
CTD |
PMID:21276781 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP3A4 protein |
CTD |
PMID:21276781 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Acan |
aggrecan |
multiple interactions |
EXP |
fisetin inhibits the reaction [IL1B protein results in decreased expression of ACAN protein] |
CTD |
PMID:38278314 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
EXP |
fisetin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein] |
CTD |
PMID:38278314 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
fisetin binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization |
ISO |
fisetin results in increased localization of AIFM1 protein |
CTD |
PMID:28181380 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
EXP ISO |
fisetin results in increased phosphorylation of AKT1 protein fisetin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:20153296 PMID:25428606 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
EXP |
fisetin results in increased expression of ALPL mRNA |
CTD |
PMID:37087476 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of APP protein] |
CTD |
PMID:31539617 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO |
fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of AR protein]; fisetin inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein]; fisetin results in decreased stability of and results in decreased expression of AR protein fisetin results in decreased expression of AR mRNA |
CTD |
PMID:18922931 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arpc5 |
actin related protein 2/3 complex, subunit 5 |
multiple interactions affects expression |
EXP |
fisetin inhibits the reaction [IL1B protein results in increased expression of ARPC5 protein] fisetin affects the expression of ARPC5 protein |
CTD |
PMID:38278314 |
|
NCBI chr13:64,904,504...64,913,413
Ensembl chr13:64,887,136...64,913,410
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of ATF6 protein] |
CTD |
PMID:28181380 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf6b |
activating transcription factor 6 beta |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of ATF6B protein] |
CTD |
PMID:28181380 |
|
NCBI chr20:4,090,921...4,098,920
Ensembl chr20:4,090,921...4,098,894
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with fisetin] results in increased expression of BAK1 protein |
CTD |
PMID:21216935 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects expression |
EXP ISO |
fisetin inhibits the reaction [Arsenic results in increased expression of BAX mRNA]; fisetin inhibits the reaction [Cisplatin results in increased expression of BAX protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of BAX protein] fisetin results in increased expression of BAX protein fisetin inhibits the reaction [Lead results in increased expression of BAX protein] fisetin affects the expression of BAX protein [fisetin co-treated with Paclitaxel] results in increased expression of BAX mRNA; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased expression of BAX protein]; U 0126 inhibits the reaction [fisetin results in increased expression of BAX protein]; XMU-MP-1 inhibits the reaction [fisetin results in increased expression of BAX protein] |
CTD |
PMID:25184746 PMID:26884726 PMID:28181380 PMID:31044527 PMID:31539617 PMID:36813806 PMID:38278314 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions affects expression decreases expression |
EXP ISO |
fisetin inhibits the reaction [Arsenic results in decreased expression of BCL2 mRNA]; fisetin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; fisetin inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein] fisetin affects the expression of BCL2 protein fisetin inhibits the reaction [Lead results in decreased expression of BCL2 protein] fisetin results in decreased expression of BCL2 protein [fisetin co-treated with Paclitaxel] results in increased expression of BCL2 mRNA |
CTD |
PMID:25184746 PMID:26884726 PMID:28181380 PMID:31539617 PMID:36813806 PMID:38278314 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; U 0126 inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; XMU-MP-1 inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:31044527 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of BDNF protein] |
CTD |
PMID:30890323 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
fisetin promotes the reaction [Lead results in increased expression of BECN1 protein] |
CTD |
PMID:31539617 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions affects expression increases cleavage |
ISO |
[Cisplatin co-treated with fisetin] results in increased cleavage of BID protein fisetin affects the expression of BID protein fisetin results in increased cleavage of BID protein |
CTD |
PMID:21216935 PMID:28181380 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with fisetin] results in decreased expression of BIRC5 protein |
CTD |
PMID:21216935 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Capn1 |
calpain 1 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of CAPN1 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CAPN1 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of CAPN2 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CAPN2 protein] |
CTD |
PMID:28181380 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp12 |
caspase 12 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of CASP12 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CASP12 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased activity of CASP3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP3 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP3 protein; [fisetin co-treated with Paclitaxel] results in increased expression of CASP3 mRNA; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; XMU-MP-1 inhibits the reaction [fisetin results in increased cleavage of CASP3 protein] fisetin inhibits the reaction [Lead results in increased cleavage of CASP3 protein] fisetin inhibits the reaction [Arsenic results in increased expression of CASP3 mRNA]; fisetin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:21216935 PMID:21964635 PMID:22931364 PMID:25184746 PMID:26884726 PMID:28181380 PMID:31044527 PMID:31539617 PMID:36813806 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of CASP4 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of CASP4 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein] |
CTD |
PMID:21216935 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [fisetin results in increased activity of CASP8 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP8 protein; fisetin results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:21216935 PMID:21964635 PMID:28181380 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
[Cisplatin co-treated with fisetin] promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; [Cisplatin co-treated with fisetin] results in increased cleavage of and results in increased activity of CASP9 protein; fisetin promotes the reaction [CASP9 protein results in increased cleavage of CASP7 protein]; fisetin results in increased cleavage of and results in increased activity of CASP9 protein fisetin results in increased activity of CASP9 protein fisetin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:21216935 PMID:25184746 PMID:28181380 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased activity of CAT protein]; fisetin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:25184746 PMID:36813806 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression multiple interactions |
ISO |
fisetin results in decreased expression of CCN2 protein [pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; U 0126 inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; XMU-MP-1 inhibits the reaction [fisetin results in decreased expression of CCN2 protein] |
CTD |
PMID:31044527 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
fisetin results in decreased expression of CCNA2 protein |
CTD |
PMID:28181380 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
[Cisplatin co-treated with fisetin] results in decreased expression of CCNB1 protein fisetin results in decreased expression of CCNB1 protein |
CTD |
PMID:21216935 PMID:28181380 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
fisetin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein] |
CTD |
PMID:16601352 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
fisetin results in decreased expression of CD44 protein |
CTD |
PMID:30802432 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
fisetin results in decreased expression of CDC25C protein |
CTD |
PMID:28181380 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of CDH1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of CDH1 protein]; fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of CDH1 protein] |
CTD |
PMID:30802432 PMID:31606474 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CDH2 protein] |
CTD |
PMID:31606474 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
fisetin results in decreased expression of CDK1 protein |
CTD |
PMID:28181380 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
fisetin results in decreased expression of CDK2 protein |
CTD |
PMID:28181380 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Cisplatin co-treated with fisetin] results in increased expression of CDKN1A protein fisetin inhibits the reaction [IL1B protein results in increased expression of CDKN1A protein] fisetin results in increased expression of CDKN1A protein |
CTD |
PMID:21216935 PMID:38278314 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
fisetin results in increased expression of CHEK1 protein |
CTD |
PMID:28181380 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
fisetin results in increased expression of CHEK2 protein |
CTD |
PMID:28181380 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
EXP |
fisetin results in increased expression of COL1A1 mRNA |
CTD |
PMID:37087476 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
affects expression multiple interactions |
EXP |
fisetin affects the expression of COL2A1 protein fisetin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 protein] |
CTD |
PMID:38278314 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
CTD |
PMID:16037419 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cplx2 |
complexin 2 |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of CPLX2 mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr17:10,219,577...10,292,835
Ensembl chr17:10,222,347...10,293,855
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
fisetin results in decreased expression of CTNNB1 protein fisetin results in increased expression of CTNNB1 mRNA; fisetin results in increased expression of CTNNB1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CTNNB1 protein] |
CTD |
PMID:30802432 PMID:31606474 PMID:37087476 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
fisetin inhibits the reaction [Cisplatin results in increased expression of CYBB mRNA] |
CTD |
PMID:25184746 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:36813806 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:36813806 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
fisetin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29584932 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23524313 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of DDIT3 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddn |
dendrin |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of DDN mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 7:129,953,317...129,957,299
Ensembl chr 7:129,953,318...129,957,341
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases activity |
ISO |
fisetin results in increased activity of DIO2 protein |
CTD |
PMID:17327447 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of DLG4 protein] |
CTD |
PMID:31539617 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[fisetin co-treated with COMT protein] results in decreased activity of DNMT1 protein |
CTD |
PMID:16037419 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of EGFR protein modified form] |
CTD |
PMID:31606474 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[fisetin co-treated with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid] results in decreased expression of EIF2AK3 protein |
CTD |
PMID:28181380 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Endog |
endonuclease G |
increases localization |
ISO |
fisetin results in increased localization of ENDOG protein |
CTD |
PMID:28181380 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
fisetin promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:20153296 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
fisetin results in decreased phosphorylation of and results in increased degradation of ERBB2 protein |
CTD |
PMID:30431692 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
fisetin results in decreased expression of ERBB3 protein |
CTD |
PMID:30431692 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Exoc8 |
exocyst complex component 8 |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of EXOC8 mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr19:52,855,010...52,857,499
Ensembl chr19:52,852,578...52,857,491
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with fisetin] results in increased expression of FASLG protein fisetin results in increased expression of FASLG protein |
CTD |
PMID:21216935 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
fisetin results in increased expression of and affects the localization of FOS protein |
CTD |
PMID:31044527 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of FSHB protein] |
CTD |
PMID:36813806 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of GDNF protein] |
CTD |
PMID:30890323 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in increased expression of GFAP protein] |
CTD |
PMID:30890323 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of GSK3B protein modified form] |
CTD |
PMID:31606474 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased activity of GSR protein]; fisetin inhibits the reaction [Cisplatin results in decreased activity of GSR protein] |
CTD |
PMID:25184746 PMID:36813806 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions affects expression |
EXP |
fisetin inhibits the reaction [IL1B protein results in increased expression of H2AX protein] fisetin affects the expression of H2AX protein |
CTD |
PMID:38278314 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression increases activity |
EXP ISO |
cobaltous chloride promotes the reaction [fisetin results in increased activity of HIF1A protein]; fisetin promotes the reaction [cobaltous chloride results in increased activity of HIF1A protein]; fisetin results in increased expression of and affects the localization of HIF1A protein fisetin promotes the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; fisetin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein] fisetin results in increased expression of HIF1A mRNA |
CTD |
PMID:20153296 PMID:25428606 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
fisetin results in increased expression of HMOX1 protein fisetin results in increased expression of HMOX1 mRNA; fisetin results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in increased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:30076913 PMID:38278314 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:36813806 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of HSD3B1 mRNA] |
CTD |
PMID:36813806 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
fisetin results in increased expression of HSPA5 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [fisetin results in increased expression of HSPA5 protein] |
CTD |
PMID:28181380 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL13 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
CTD |
PMID:12789233 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL1B protein] fisetin inhibits the reaction [IL1B protein results in decreased expression of ACAN protein]; fisetin inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; fisetin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 protein]; fisetin inhibits the reaction [IL1B protein results in decreased expression of SIRT6 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of ARPC5 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of BAX protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of CDKN1A protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of H2AX protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:18958421 PMID:38278314 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression |
ISO |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL4 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] fisetin results in decreased expression of IL4 protein |
CTD |
PMID:12789233 PMID:16343431 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
fisetin inhibits the reaction [[Calcimycin co-treated with phorbol-12-myristate] results in increased expression of IL5 protein]; fisetin inhibits the reaction [Calcimycin results in increased expression of IL5 mRNA] |
CTD |
PMID:12789233 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of IL6 protein]; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA] fisetin inhibits the reaction [Lead results in increased expression of IL6 protein] |
CTD |
PMID:18958421 PMID:22931364 PMID:31539617 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]; fisetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] |
CTD |
PMID:18591783 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
fisetin results in increased phosphorylation of and affects the localization of JUN protein |
CTD |
PMID:31044527 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression multiple interactions |
ISO |
fisetin results in decreased expression of KLK3 mRNA fisetin inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; fisetin results in decreased expression of and results in decreased secretion of KLK3 protein |
CTD |
PMID:18922931 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lats2 |
large tumor suppressor kinase 2 |
increases phosphorylation |
ISO |
fisetin results in increased phosphorylation of LATS2 protein |
CTD |
PMID:31044527 |
|
NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of LHB protein] |
CTD |
PMID:36813806 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lin7a |
lin-7 homolog A, crumbs cell polarity complex component |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of LIN7A mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550
|
|
G |
Map3k20 |
mitogen-activated protein kinase kinase kinase 20 |
increases expression |
ISO |
fisetin results in increased expression of MAP3K20 protein |
CTD |
PMID:31044527 |
|
NCBI chr 3:57,130,539...57,289,943
Ensembl chr 3:57,130,551...57,289,626
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
fisetin results in increased phosphorylation of MAPK1 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21964635 PMID:25428606 PMID:31044527 PMID:31606474 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
fisetin results in increased phosphorylation of MAPK3 protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21964635 PMID:25428606 PMID:31044527 PMID:31606474 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased phosphorylation of MAPT protein] |
CTD |
PMID:31539617 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of MME protein] |
CTD |
PMID:31539617 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions affects expression |
EXP |
fisetin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] fisetin affects the expression of MMP13 protein |
CTD |
PMID:38278314 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP2 protein]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 protein] fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MMP2 protein] fisetin results in decreased expression of MMP2 mRNA; fisetin results in decreased expression of MMP2 protein |
CTD |
PMID:30076913 PMID:31606474 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
fisetin inhibits the reaction [Silicon Dioxide results in increased expression of MMP9 mRNA]; fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MMP9 protein] HMOX1 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; tin protoporphyrin IX inhibits the reaction [fisetin results in decreased expression of MMP9 protein]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 protein] fisetin results in decreased expression of MMP9 mRNA; fisetin results in decreased expression of MMP9 protein |
CTD |
PMID:22931364 PMID:30076913 PMID:31606474 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
fisetin inhibits the reaction [Cisplatin results in increased activity of MPO protein] |
CTD |
PMID:25184746 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of MYD88 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Calcimycin results in increased activity of NFATC2 protein] |
CTD |
PMID:12789233 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
ISO EXP |
fisetin results in increased expression of NFE2L2 protein NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP2 protein]; NFE2L2 protein promotes the reaction [fisetin results in decreased expression of MMP9 protein]; NFE2L2 protein promotes the reaction [fisetin results in increased expression of HMOX1 protein] |
CTD |
PMID:16799064 PMID:30076913 PMID:38278314 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
fisetin results in decreased expression of NFKB1 protein |
CTD |
PMID:30802432 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
fisetin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:25184746 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
fisetin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; fisetin inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] fisetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:17177504 PMID:25184746 PMID:38278314 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Cisplatin results in increased expression of NOX4 mRNA] |
CTD |
PMID:25184746 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
fisetin inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein] |
CTD |
PMID:25184746 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
fisetin results in increased expression of NR1I2 mRNA |
CTD |
PMID:29933105 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nrgn |
neurogranin |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of NRGN mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases activity |
ISO |
fisetin results in decreased activity of PARP1 protein |
CTD |
PMID:17884996 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
ISO |
fisetin results in decreased expression of PROM1 protein |
CTD |
PMID:30802432 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
fisetin inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:38278314 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] affects the localization of and results in increased activity of RELA protein] fisetin inhibits the reaction [Lead affects the localization of RELA protein] fisetin inhibits the reaction [Cisplatin affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:18958421 PMID:25184746 PMID:31539617 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
EXP |
ICG 001 inhibits the reaction [fisetin results in increased expression of RUNX2 protein] fisetin results in increased expression of RUNX2 mRNA; fisetin results in increased expression of RUNX2 protein |
CTD |
PMID:37087476 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of SIRT1 protein]; fisetin results in increased activity of and results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:31539617 PMID:34216621 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt6 |
sirtuin 6 |
multiple interactions affects expression |
EXP |
fisetin inhibits the reaction [IL1B protein results in decreased expression of SIRT6 protein] fisetin affects the expression of SIRT6 protein |
CTD |
PMID:38278314 |
|
NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[fisetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
ISO |
[fisetin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:20153296 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in decreased expression of SNAP25 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions increases expression |
EXP |
ICG 001 inhibits the reaction [fisetin results in increased expression of SPP1 protein] fisetin results in increased expression of SPP1 mRNA; fisetin results in increased expression of SPP1 protein |
CTD |
PMID:37087476 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
ISO |
fisetin results in increased expression of SREBF2 protein alternative form |
CTD |
PMID:23524313 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
fisetin inhibits the reaction [Arsenic results in decreased expression of STAR mRNA] |
CTD |
PMID:36813806 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
fisetin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of STAT3 protein] fisetin results in decreased expression of STAT3 protein |
CTD |
PMID:20153296 PMID:30802432 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions |
EXP |
fisetin inhibits the reaction [methylmercuric chloride results in decreased expression of STX1A mRNA] |
CTD |
PMID:30890323 |
|
NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
fisetin inhibits the reaction [Lead results in increased expression of TLR4 protein] |
CTD |
PMID:31539617 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; fisetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased secretion of TNF protein] fisetin inhibits the reaction [Lead results in increased expression of TNF protein] fisetin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:18958421 PMID:25184746 PMID:31539617 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects localization increases expression |
ISO EXP |
[Cisplatin co-treated with fisetin] affects the localization of TP53 protein; [Cisplatin co-treated with fisetin] results in increased expression of TP53 protein; [Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein; fisetin inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA]; SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein] fisetin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] fisetin affects the localization of TP53 protein fisetin results in increased expression of TP53 protein |
CTD |
PMID:21216935 PMID:22931364 PMID:25184746 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of fisetin |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
fisetin inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; fisetin inhibits the reaction [Oxygen deficiency results in increased secretion of VEGFA protein]; fisetin promotes the reaction [Oxygen deficiency results in increased expression of and results in increased localization of VEGFA protein] |
CTD |
PMID:20153296 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression multiple interactions |
ISO |
fisetin results in decreased expression of VIM protein fisetin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of VIM protein] |
CTD |
PMID:30802432 PMID:31606474 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt3 |
Wnt family member 3 |
increases expression |
EXP |
fisetin results in increased expression of WNT3 mRNA; fisetin results in increased expression of WNT3 protein |
CTD |
PMID:37087476 |
|
NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
fisetin results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:31044527 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of ABCC1 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of ACTA2 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
homoorientin results in decreased phosphorylation of AKT1 protein homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of AKT1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA] |
CTD |
PMID:22446813 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
homoorientin results in increased expression of CDH1 protein |
CTD |
PMID:34019859 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of CDH2 protein |
CTD |
PMID:34019859 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of CTNNB1 protein |
CTD |
PMID:34019859 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
ISO |
homoorientin results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:34019859 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of LEF1 protein |
CTD |
PMID:34019859 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK1 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:24374571 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
homoorientin promotes the reaction [Zinc Oxide analog results in decreased phosphorylation of MAPK3 protein]; Zinc Oxide analog promotes the reaction [homoorientin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:24374571 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
decreases expression |
ISO |
homoorientin results in decreased expression of MMP7 protein |
CTD |
PMID:34019859 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:22446813 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
homoorientin results in decreased expression of POU5F1 protein |
CTD |
PMID:34019859 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of SNAI2 protein |
CTD |
PMID:34019859 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
homoorientin results in decreased expression of SOX2 protein |
CTD |
PMID:34019859 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases expression decreases phosphorylation |
ISO |
homoorientin results in decreased expression of STAT3 protein modified form homoorientin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tcf7 |
transcription factor 7 |
decreases expression |
ISO |
homoorientin results in decreased expression of TCF7 protein |
CTD |
PMID:34019859 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of TGFB1 protein] |
CTD |
PMID:22446813 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
homoorientin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:22446813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
homoorientin results in decreased expression of VIM protein |
CTD |
PMID:34019859 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity decreases expression multiple interactions |
ISO |
Luteolin results in increased activity of ABCB1 protein Luteolin results in decreased expression of ABCB1 protein Luteolin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin] |
CTD |
PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Luteolin co-treated with Cisplatin] results in increased expression of ABCC2 protein; Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:23770416 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of ABCC4 protein] |
CTD |
PMID:23770416 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects activity |
ISO |
Luteolin affects the activity of ABCG2 protein |
CTD |
PMID:20403331 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [cobaltous chloride results in increased activity of ACHE protein] |
CTD |
PMID:31362009 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:19747501 PMID:37308028 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA] |
CTD |
PMID:19557821 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Luteolin binds to and results in decreased activity of AHR protein Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:14644660 PMID:20450880 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression decreases phosphorylation increases phosphorylation |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein] Luteolin results in decreased expression of AKT1 mRNA Luteolin results in decreased phosphorylation of AKT1 protein Luteolin results in increased phosphorylation of AKT1 protein Luteolin inhibits the reaction [Antimycin A results in decreased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in decreased expression of AKT1 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein] [Luteolin co-treated with Hydrogen Peroxide] results in increased expression of AKT1 protein; Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased phosphorylation of AKT1 protein] Luteolin results in decreased expression of AKT1 mRNA; Luteolin results in decreased expression of AKT1 protein |
CTD |
PMID:18591783 PMID:18720166 PMID:19344998 PMID:20153296 PMID:20685402 PMID:21782929 PMID:22926442 PMID:25448439 PMID:27474067 PMID:27525270 PMID:32035215 PMID:36819991 PMID:37379125 PMID:38134066 PMID:38230768 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:18096136 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of ASNS mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of ATF6 protein modified form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of ATF6 protein modified form] |
CTD |
PMID:32407927 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
EXP ISO |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of ATG5 protein] Luteolin results in increased expression of ATG5 protein |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases expression |
EXP |
Luteolin results in increased expression of ATP7B mRNA |
CTD |
PMID:31201582 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of BAX protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of BAX protein] Luteolin results in increased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of BAX protein]; Luteolin affects the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased expression of BAX protein]; Luteolin affects the reaction [Metals, Heavy results in increased expression of BAX protein] |
CTD |
PMID:21601631 PMID:27474067 PMID:27525270 PMID:29115570 PMID:32035215 PMID:32268164 PMID:38103742 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of BCL2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2 protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] Luteolin inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:19557821 PMID:25448439 PMID:27474067 PMID:32268164 PMID:38103742 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Luteolin results in decreased expression of BCL2L1 protein Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of BCL2L1 protein] |
CTD |
PMID:21601631 PMID:25448439 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
ISO EXP |
Luteolin results in increased expression of BECN1 protein Luteolin inhibits the reaction [Methamphetamine results in increased expression of BECN1 protein] |
CTD |
PMID:32035215 PMID:32268164 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] |
CTD |
PMID:15334063 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased cleavage of CASP1 protein] Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] |
CTD |
PMID:25450234 PMID:34217685 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases cleavage increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased cleavage of CASP3 protein]; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin results in increased expression of and results in increased cleavage of CASP3 protein Luteolin results in increased expression of CASP3 mRNA Luteolin results in increased expression of CASP3 protein Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] Luteolin results in increased activity of CASP3 protein Luteolin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased expression of CASP3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:16140950 PMID:18331776 PMID:19397994 PMID:21074525 PMID:21601631 PMID:23770416 PMID:24525192 PMID:27474067 PMID:27489195 PMID:27525270 PMID:29115570 PMID:31201582 PMID:31288002 PMID:32035215 PMID:32268164 PMID:32407927 PMID:33727136 PMID:33827303 PMID:38134066 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Luteolin results in increased activity of CASP7 protein |
CTD |
PMID:21074525 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
[Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein] Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein] |
CTD |
PMID:15334063 PMID:16140950 PMID:24525192 PMID:27525270 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases cleavage |
ISO EXP |
Luteolin results in increased activity of CASP9 protein Luteolin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of CASP9 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of CASP9 protein] Luteolin results in increased cleavage of CASP9 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:21601631 PMID:27474067 PMID:27489195 PMID:29115570 PMID:33827303 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
affects activity multiple interactions decreases activity |
ISO EXP |
Luteolin affects the activity of CAT protein Luteolin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein] Luteolin results in decreased activity of CAT protein Fluorouracil promotes the reaction [Luteolin results in decreased activity of CAT protein]; Luteolin inhibits the reaction [Doxorubicin results in increased activity of CAT protein]; Luteolin promotes the reaction [Fluorouracil results in decreased activity of CAT protein] |
CTD |
PMID:18503759 PMID:31288002 PMID:33827303 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein] |
CTD |
PMID:24134915 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn5 |
cellular communication network factor 5 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCN5 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCNA2 protein |
CTD |
PMID:22926442 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CCNB1 mRNA; Luteolin results in decreased expression of CCNB1 protein |
CTD |
PMID:18331776 PMID:19397994 PMID:22926442 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Fluorouracil promotes the reaction [Luteolin results in decreased expression of CCND1 protein]; Luteolin promotes the reaction [Fluorouracil results in decreased expression of CCND1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of CD40 protein]; Luteolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD40 protein] |
CTD |
PMID:16601352 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Luteolin results in decreased expression of CD74 mRNA |
CTD |
PMID:18818744 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased expression of CDH1 protein] |
CTD |
PMID:27474067 PMID:32268164 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in decreased expression of CDH2 protein] |
CTD |
PMID:27474067 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CDH5 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CDK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity decreases expression |
ISO |
Luteolin results in decreased activity of CDK2 protein Luteolin results in decreased expression of CDK2 protein |
CTD |
PMID:11322924 PMID:22926442 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression affects localization multiple interactions |
ISO EXP |
Luteolin results in increased expression of CDKN1A mRNA; Luteolin results in increased expression of CDKN1A protein Luteolin affects the localization of CDKN1A protein Fluorouracil promotes the reaction [Luteolin results in increased expression of CDKN1A protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of CDKN1A protein] |
CTD |
PMID:11322924 PMID:11790449 PMID:19397994 PMID:22926442 PMID:31201582 PMID:31288002 PMID:32268164 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Luteolin results in increased expression of CDKN1B protein |
CTD |
PMID:11322924 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Luteolin results in decreased expression of CDKN2C mRNA |
CTD |
PMID:18331776 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
EXP |
Luteolin results in decreased activity of CES1 protein |
CTD |
PMID:37353134 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of CHUK protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein] |
CTD |
PMID:25448439 PMID:37390879 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 protein]; Luteolin promotes the reaction [decabromobiphenyl ether results in decreased expression of CLDN1 mRNA] |
CTD |
PMID:33675858 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression multiple interactions |
ISO EXP |
Luteolin results in decreased expression of CSF2 mRNA Luteolin inhibits the reaction [Calcimycin results in increased expression of CSF2 mRNA] |
CTD |
PMID:10718847 PMID:17950587 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of CTNNB1 protein |
CTD |
PMID:32268164 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of CXCL12 mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL9 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Luteolin results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases response to substance decreases expression increases expression decreases activity |
ISO |
[CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Dust analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of CYP1A1 mRNA] Luteolin results in decreased expression of CYP1A1 protein Luteolin results in increased expression of CYP1A1 mRNA Luteolin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] Luteolin results in decreased activity of CYP1A1 protein |
CTD |
PMID:16263508 PMID:17090139 PMID:20403331 PMID:20930378 PMID:21482471 PMID:23994263 PMID:29584932 PMID:33727136 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases response to substance multiple interactions decreases expression |
ISO |
Luteolin results in decreased activity of CYP1A2 protein CYP1A2 protein results in increased susceptibility to Luteolin [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of CASP3 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein] Luteolin results in decreased expression of CYP1A2 protein |
CTD |
PMID:29753067 PMID:33727136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity increases expression |
ISO |
Luteolin results in decreased activity of CYP1B1 protein Luteolin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21482471 PMID:23994263 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
Luteolin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:23770416 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Luteolin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] |
CTD |
PMID:32407927 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Derl3 |
derlin 3 |
increases expression |
EXP |
Luteolin results in increased expression of DERL3 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases activity |
ISO |
Luteolin results in decreased activity of DHRS11 protein |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of DNAJB9 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of DRAM1 protein Fluorouracil promotes the reaction [Luteolin results in increased expression of DRAM1 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of DRAM1 protein] |
CTD |
PMID:31288002 |
|
NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions affects response to substance |
ISO |
Luteolin results in decreased expression of EGFR mRNA EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of EGFR protein]; Luteolin affects the activity of and results in decreased phosphorylation of EGFR protein; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Luteolin results in decreased phosphorylation of and results in increased activity of EGFR protein EGFR protein affects the susceptibility to Luteolin |
CTD |
PMID:10556937 PMID:12168845 PMID:15135307 PMID:22926442 PMID:36819991 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Luteolin results in increased expression of EGR1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased phosphorylation of EIF2S1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of and results in increased phosphorylation of ERN1 protein]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of and results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32407927 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding multiple interactions |
ISO |
Luteolin binds to ESR1 protein Luteolin inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:14579009 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity affects binding |
ISO |
Luteolin results in increased activity of ESR2 protein Luteolin binds to ESR2 protein |
CTD |
PMID:12224631 PMID:16860978 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F11r |
F11 receptor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of F11R mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP |
Luteolin results in increased expression of FAS mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of FASN mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of FBP1 mRNA |
CTD |
PMID:18331776 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases activity |
ISO EXP |
Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA] Luteolin inhibits the reaction [Calcimycin results in increased expression of FOS mRNA] Luteolin results in decreased activity of FOS protein |
CTD |
PMID:15322261 PMID:16343431 PMID:17950587 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of FOSB protein |
CTD |
PMID:16343431 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
Luteolin results in increased expression of and results in increased phosphorylation of FOXO3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein] |
CTD |
PMID:32268164 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Luteolin results in increased expression of GADD45B mRNA; Luteolin results in increased expression of GADD45B protein |
CTD |
PMID:18331776 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
Luteolin results in increased expression of GCLC mRNA; Luteolin results in increased expression of GCLC protein [Luteolin results in increased expression of GCLC mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide |
CTD |
PMID:22864849 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
EXP |
Luteolin results in increased expression of GCLM mRNA; Luteolin results in increased expression of GCLM protein |
CTD |
PMID:22864849 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Carbon Tetrachloride results in increased expression of GFAP protein] |
CTD |
PMID:19747501 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
multiple interactions |
EXP ISO |
Luteolin binds to and results in increased activity of GPR35 protein |
CTD |
PMID:20919992 |
|
NCBI chr 9:93,527,165...93,539,573
Ensembl chr 9:93,527,127...93,539,299
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of GPT protein] |
CTD |
PMID:33827303 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Luteolin co-treated with 4(G)-alpha-glucopyranosyl-rutin] inhibits the reaction [Doxorubicin results in decreased activity of GPX1 protein] |
CTD |
PMID:9242351 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of GSDMD protein] |
CTD |
PMID:34217685 PMID:37379125 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
EXP |
Luteolin results in increased expression of GSTA1 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
increases expression |
EXP |
Luteolin results in increased expression of GSTT2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
CYP1A1 protein promotes the reaction [Luteolin results in increased expression of H2AX protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased expression of H2AX protein] |
CTD |
PMID:33727136 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of HIF1A protein]; Luteolin inhibits the reaction [Oxygen deficiency results in increased activity of HIF1A protein]; Luteolin promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Luteolin results in increased expression of and results in increased activity of HIF1A protein Luteolin results in decreased activity of HIF1A protein |
CTD |
PMID:19958256 PMID:20153296 PMID:25448439 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of HMOX1 protein] Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; Luteolin promotes the reaction [Irinotecan results in increased expression of HMOX1 mRNA] Luteolin results in increased expression of HMOX1 mRNA; Luteolin results in increased expression of HMOX1 protein [Luteolin results in increased expression of HMOX1 mRNA] which results in decreased susceptibility to tert-Butylhydroperoxide; Luteolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein] |
CTD |
PMID:10975858 PMID:22864849 PMID:31091348 PMID:32268164 PMID:34217685 PMID:34699766 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
decreases expression |
EXP |
Luteolin results in decreased expression of HSD17B7 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein] |
CTD |
PMID:32407927 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:15113938 PMID:15322261 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO EXP |
Luteolin results in increased expression of IFNG protein Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:12755373 PMID:18090225 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Luteolin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein] Luteolin inhibits the reaction [nickel chloride results in increased expression of IL10 protein] |
CTD |
PMID:16934226 PMID:30016632 PMID:33827303 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL13 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein] |
CTD |
PMID:25450234 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of IL1B protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of IL1B mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL1B protein] Luteolin results in decreased expression of IL1B protein Luteolin results in decreased expression of IL1B mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [Rotenone results in increased secretion of IL1B protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL1B protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; Luteolin inhibits the reaction [lipoteichoic acid results in increased expression of IL1B] |
CTD |
PMID:18090225 PMID:18946510 PMID:19557821 PMID:20685402 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 PMID:30207190 PMID:31091348 PMID:31362009 PMID:33675858 PMID:33827303 PMID:34217685 PMID:34699766 PMID:37390879 PMID:37563784 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il27 |
interleukin 27 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL27 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] |
CTD |
PMID:19426678 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Calcimycin results in increased expression of IL3 mRNA] |
CTD |
PMID:17950587 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il33 |
interleukin 33 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Irinotecan results in increased expression of IL33 mRNA]; Luteolin inhibits the reaction [Irinotecan results in increased secretion of IL33 protein] |
CTD |
PMID:34699766 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL4] Luteolin inhibits the reaction [Calcimycin results in increased expression of IL4 mRNA] Luteolin results in decreased expression of IL4 protein |
CTD |
PMID:12755373 PMID:16343431 PMID:16601352 PMID:17950587 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases expression |
ISO |
Luteolin results in decreased expression of IL5 protein |
CTD |
PMID:12755373 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL6 protein]; Luteolin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [nickel chloride results in increased expression of IL6 protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [bisphenol A results in decreased expression of IL6 protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 protein] |
CTD |
PMID:11123379 PMID:18720166 PMID:19426678 PMID:24134915 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31091348 PMID:33675858 PMID:37379125 PMID:37390879 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]; Luteolin inhibits the reaction [INS1 protein results in increased activity of AKT1 protein]; Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]; Luteolin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in decreased secretion of INS1 protein]; Luteolin inhibits the reaction [Fructose results in increased expression of INS1 protein] |
CTD |
PMID:18090225 PMID:18591783 PMID:25169908 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:18591783 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Lipopolysaccharides promotes the reaction [IRF3 protein binds to IRF3 protein]]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:19426678 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of JAK1 protein] |
CTD |
PMID:38103742 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression decreases phosphorylation |
ISO EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of JUN protein Luteolin results in decreased expression of JUN mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein] Luteolin results in decreased phosphorylation of JUN protein |
CTD |
PMID:15322261 PMID:15334063 PMID:16343431 PMID:17950587 PMID:30133131 PMID:37390879 PMID:38134066 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of JUNB protein |
CTD |
PMID:16343431 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
Luteolin results in decreased activity of JUND protein |
CTD |
PMID:16343431 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of KEAP1 protein] |
CTD |
PMID:33675858 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
[Rotenone co-treated with Luteolin] results in increased expression of LRRK2 mRNA; Luteolin inhibits the reaction [Rotenone results in increased expression of LRRK2 mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
EXP |
Luteolin results in decreased expression of LSS mRNA |
CTD |
PMID:31201582 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity multiple interactions |
ISO |
Luteolin results in decreased activity of MAOA protein Luteolin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin] |
CTD |
PMID:23009399 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein; mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32268164 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression decreases phosphorylation increases phosphorylation increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein] Luteolin results in decreased expression of MAPK1 mRNA Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Luteolin results in decreased phosphorylation of MAPK1 protein Luteolin results in increased activity of MAPK1 protein |
CTD |
PMID:10718847 PMID:15322261 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:22864849 PMID:25448439 PMID:27474067 PMID:32268164 PMID:33675858 PMID:36819991 PMID:37390879 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
increases phosphorylation |
ISO |
Luteolin results in increased phosphorylation of MAPK10 protein |
CTD |
PMID:21601631 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation increases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of MAPK3 protein]; Luteolin inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein] Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Luteolin results in decreased phosphorylation of MAPK3 protein Luteolin inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Luteolin results in increased activity of MAPK3 protein |
CTD |
PMID:10718847 PMID:17950587 PMID:17982879 PMID:19344998 PMID:19557821 PMID:20685402 PMID:25448439 PMID:27474067 PMID:32268164 PMID:33675858 PMID:37390879 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; Luteolin results in decreased phosphorylation of and results in decreased activity of MAPK8 protein Luteolin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:10718847 PMID:15334063 PMID:21601631 PMID:30133131 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Luteolin results in increased phosphorylation of MAPK9 protein Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:21601631 PMID:30133131 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Luteolin results in decreased expression of MCL1 protein |
CTD |
PMID:33727136 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
EXP |
Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA] Luteolin results in increased expression of MDM2 mRNA |
CTD |
PMID:27525270 PMID:31201582 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir320a |
microRNA 320a |
multiple interactions |
EXP |
luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in nucleus] |
RGD |
PMID:31089916 |
RGD:155882543 |
NCBI chr15:45,516,392...45,516,473
Ensembl chr15:45,516,392...45,516,473
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of MMP1 mRNA; Luteolin results in decreased expression of MMP1 protein |
CTD |
PMID:21112745 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression decreases secretion |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of MMP9 protein]; Luteolin inhibits the reaction [EGF protein results in increased secretion of MMP9 protein] Luteolin results in increased expression of MMP9 protein Luteolin inhibits the reaction [Carbon Tetrachloride results in decreased expression of MMP9 protein] Luteolin results in decreased secretion of MMP9 protein |
CTD |
PMID:10556937 PMID:15135307 PMID:19747501 PMID:25448439 PMID:30133131 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of MPO protein] |
CTD |
PMID:33827303 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYLK protein]] |
CTD |
PMID:33675858 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Sodium Chloride results in increased expression of NFAT5 mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
decreases expression |
EXP |
Luteolin results in decreased expression of NFE2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity |
EXP ISO |
[Luteolin results in increased activity of NFE2L2 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; Luteolin affects the localization of and results in increased activity of NFE2L2 protein; Luteolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein] luteolin inhibits the reaction [ischemia-reperfusion injury increases expression of Nfe2l2 protein in nucleus] Luteolin promotes the reaction [Rotenone results in increased expression of NFE2L2 mRNA] [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NFE2L2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NFE2L2 mRNA]; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein |
CTD RGD |
PMID:17982879 PMID:22864849 PMID:30207190 PMID:31091348 PMID:32407927 PMID:33675858 PMID:34217685 PMID:34699766 PMID:31089916 More...
|
RGD:155882543 |
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of and affects the localization of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:15334063 PMID:18090225 PMID:33675858 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased degradation of NFKBIA protein] Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:11123379 PMID:15322261 PMID:16934226 PMID:18090225 PMID:19557821 PMID:25448439 PMID:33675858 PMID:37390879 More...
|
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]] |
CTD |
PMID:15322261 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of NLRP1A protein] |
CTD |
PMID:25450234 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] |
CTD |
PMID:34217685 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] Luteolin results in decreased expression of NOS2 mRNA Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of NOS2 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NOS2 mRNA] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 PMID:18090225 PMID:19426678 PMID:25448439 PMID:34699766 PMID:37379125 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Luteolin co-treated with linarin] results in increased expression of NOS3 protein modified form |
CTD |
PMID:29052401 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of NQO1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]] |
CTD |
PMID:33675858 PMID:34699766 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of NR1D1 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
Luteolin results in decreased expression of NSDHL mRNA |
CTD |
PMID:31201582 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of OCLN protein] |
CTD |
PMID:33675858 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of P2RX4 protein] |
CTD |
PMID:25450234 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
[Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; CYP1A1 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; CYP1A2 protein promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [[Lead co-treated with Cadmium co-treated with Mercury co-treated with Copper co-treated with Zinc co-treated with Manganese co-treated with Chromium co-treated with Nickel] results in increased cleavage of PARP1 protein]; Luteolin inhibits the reaction [Metals, Heavy results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein] Luteolin inhibits the reaction [Tunicamycin results in increased expression of PARP1 protein modified form] |
CTD |
PMID:12168845 PMID:24525192 PMID:29115570 PMID:31201582 PMID:32268164 PMID:32407927 PMID:33727136 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PDGFB mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
Luteolin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
Luteolin results in decreased expression of PLK1 protein |
CTD |
PMID:22926442 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of PPARG mRNA [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; Luteolin inhibits the reaction [Irinotecan results in decreased expression of PPARG mRNA]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of NQO1 mRNA]]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] |
CTD |
PMID:34699766 PMID:37308028 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]] |
CTD |
PMID:37308028 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] |
CTD |
PMID:30133131 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Rotenone co-treated with Luteolin] results in increased expression of PRKN mRNA; Luteolin inhibits the reaction [Rotenone results in decreased expression of PRKN mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Psca |
prostate stem cell antigen |
decreases expression |
ISO |
Luteolin results in decreased expression of PSCA mRNA |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of PTEN protein] |
CTD |
PMID:32035215 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Dust analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Dust results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Luteolin inhibits the reaction [Particulate Matter analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions analog results in increased expression of PTGS2 mRNA]; Luteolin inhibits the reaction [Vehicle Emissions results in increased expression of PTGS2 mRNA] Luteolin results in increased expression of PTGS2 mRNA Luteolin inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:16263508 PMID:19557821 PMID:23770416 PMID:25448439 PMID:31201582 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
ISO |
EGF protein inhibits the reaction [Luteolin results in decreased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of PTK2 protein]; Luteolin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:15135307 PMID:25448439 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of PYCARD protein] |
CTD |
PMID:25450234 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
luteolin decreases expression of RAC1 protein in lung cancer cells |
RGD |
PMID:32256987 |
RGD:153345548 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
Luteolin analog inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; Luteolin inhibits the reaction [chromium hexavalent ion results in increased activity of and affects the localization of RELA protein]; Luteolin inhibits the reaction [Glucose affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein] Luteolin inhibits the reaction [Cisplatin results in increased expression of RELA protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] affects the localization of and results in increased activity of RELA protein] |
CTD |
PMID:15113938 PMID:15334063 PMID:18090225 PMID:19557821 PMID:23770416 PMID:25448439 PMID:30133131 PMID:34217685 PMID:37390879 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:15113938 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sesn2 |
sestrin 2 |
increases expression multiple interactions |
ISO |
Luteolin results in increased expression of SESN2 mRNA; Luteolin results in increased expression of SESN2 protein Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 mRNA]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of SESN2 protein] [Luteolin results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; SESN2 protein promotes the reaction [Luteolin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] |
CTD |
PMID:32407927 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Luteolin results in increased expression of SFN mRNA; Luteolin results in increased expression of SFN protein |
CTD |
PMID:18331776 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[[Luteolin co-treated with Phloretin] results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate; [Luteolin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
decreases activity |
ISO |
Luteolin results in decreased activity of SLC22A6 protein |
CTD |
PMID:32159797 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
decreases activity |
ISO |
Luteolin results in decreased activity of SLC22A8 protein |
CTD |
PMID:32159797 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] |
CTD |
PMID:36870413 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
ISO |
[Luteolin co-treated with Oxygen deficiency] results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:20153296 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slco1c1 |
solute carrier organic anion transporter family, member 1c1 |
decreases activity multiple interactions |
EXP |
Luteolin results in decreased activity of SLCO1B1 protein [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of SNAI1 protein] |
CTD |
PMID:33675858 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects activity increases expression multiple interactions |
ISO |
Luteolin affects the activity of SOD1 protein Luteolin results in increased expression of SOD1 mRNA Luteolin inhibits the reaction [Irinotecan results in decreased expression of SOD1 protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of SOD1 mRNA] Luteolin inhibits the reaction [Carbon Tetrachloride results in increased activity of SOD1 protein] |
CTD |
PMID:18503759 PMID:19747501 PMID:34699766 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Luteolin results in increased expression of SOD2 protein |
CTD |
PMID:32268164 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Tunicamycin results in increased expression of SREBF1 mRNA] |
CTD |
PMID:32407927 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
EXP |
Luteolin results in increased expression of STAR mRNA; Luteolin results in increased expression of STAR protein |
CTD |
PMID:31201582 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of STAT3 protein]; Luteolin promotes the reaction [Paclitaxel results in decreased phosphorylation of STAT3 protein]; Paclitaxel promotes the reaction [Luteolin results in decreased phosphorylation of STAT3 protein] Luteolin inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:24525192 PMID:25448439 PMID:38103742 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of TBK1 protein |
CTD |
PMID:19426678 |
|
NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; [kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PPARG mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in decreased expression of PRKAA1 mRNA]]; dorsomorphin inhibits the reaction [[kaempferol co-treated with Luteolin] inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]]; Luteolin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:37308028 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 mRNA]; Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]; ML 7 inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]]; triptolide inhibits the reaction [Luteolin inhibits the reaction [decabromobiphenyl ether results in decreased expression of TJP1 protein]] |
CTD |
PMID:33675858 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
Luteolin results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:31201582 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Luteolin inhibits the reaction [chromium hexavalent ion results in increased secretion of TNF protein]; Luteolin inhibits the reaction [decabromobiphenyl ether results in increased expression of TNF protein]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Glucose results in increased expression of TNF protein]; Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [nickel chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [TNF protein affects the localization of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of [FOS protein binds to JUN protein]]; Luteolin inhibits the reaction [TNF protein results in increased activity of MAPK1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Luteolin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Luteolin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of SELE protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Luteolin inhibits the reaction [TNF protein results in increased phosphorylation of [NFKBIB protein binds to NFKBIA protein]]; Luteolin promotes the reaction [TNF protein results in increased cleavage of and results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of JUN protein]; Luteolin promotes the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; PPARG protein affects the reaction [Luteolin inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]] Luteolin results in decreased expression of TNF protein Luteolin results in decreased expression of TNF mRNA Luteolin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Luteolin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of IL6 protein] Luteolin inhibits the reaction [bisphenol A results in decreased expression of TNF protein]; Luteolin inhibits the reaction [Calcimycin results in increased expression of TNF mRNA]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; Luteolin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Luteolin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein] |
CTD |
PMID:11123379 PMID:15113938 PMID:15322261 PMID:15334063 PMID:16934226 PMID:17950587 PMID:18720166 PMID:19426678 PMID:19557821 PMID:23770416 PMID:25448439 PMID:25450234 PMID:30016632 PMID:31091348 PMID:31362009 PMID:33675858 PMID:33827303 PMID:34699766 PMID:37379125 PMID:37563784 PMID:38134066 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:15334063 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] |
CTD |
PMID:16140950 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions |
EXP |
Luteolin binds to and results in decreased activity of TOP1 protein |
CTD |
PMID:12027807 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression increases expression |
ISO EXP |
Fluorouracil promotes the reaction [Luteolin results in increased expression of TRP53 protein]; Luteolin inhibits the reaction [Cisplatin results in increased expression of TRP53 protein]; Luteolin promotes the reaction [Fluorouracil results in increased expression of TRP53 protein] Luteolin results in decreased expression of TRP53 mRNA Luteolin results in increased expression of TP53 mRNA Luteolin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; Luteolin inhibits the reaction [Methamphetamine results in increased expression of TP53 protein] |
CTD |
PMID:23770416 PMID:27525270 PMID:31201582 PMID:31288002 PMID:32035215 PMID:36819991 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Luteolin results in increased expression of TP53I3 mRNA; Luteolin results in increased expression of TP53I3 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Tp63 |
tumor protein p63 |
increases expression |
ISO |
Luteolin results in increased expression of TP63 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tp73 |
tumor protein p73 |
increases expression |
ISO |
Luteolin results in increased expression of TP73 protein |
CTD |
PMID:18331776 PMID:19397994 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
Luteolin promotes the reaction [Rotenone results in increased expression of TXN1 mRNA] |
CTD |
PMID:30207190 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
ISO |
Luteolin results in decreased activity of TXNRD1 protein |
CTD |
PMID:31288002 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Luteolin results in increased expression of TYR mRNA |
CTD |
PMID:21071833 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions increases expression |
ISO |
Luteolin inhibits the reaction [Benzo(a)pyrene results in increased expression of UGT1A1 mRNA] Luteolin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:20403331 PMID:29584932 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
affects glucuronidation increases glucuronidation |
ISO |
UGT1A3 mutant form affects the glucuronidation of Luteolin UGT1A3 protein results in increased glucuronidation of Luteolin |
CTD |
PMID:16738032 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Luteolin |
CTD |
PMID:32009392 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vav3 |
vav guanine nucleotide exchange factor 3 |
decreases expression |
ISO |
Luteolin results in decreased expression of VAV3 mRNA |
CTD |
PMID:19397994 |
|
NCBI chr 2:197,011,901...197,354,321
Ensembl chr 2:197,011,831...197,354,321
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; Luteolin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:15113938 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression multiple interactions |
ISO |
Luteolin results in decreased expression of VEGFA mRNA; Luteolin results in decreased expression of VEGFA protein Luteolin inhibits the reaction [chromium hexavalent ion results in increased expression of VEGFA protein]; Luteolin inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; Luteolin inhibits the reaction [Oxygen deficiency results in increased secretion of VEGFA protein] |
CTD |
PMID:19005980 PMID:20153296 PMID:25448439 PMID:26800359 PMID:36819991 PMID:38134066 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Methamphetamine results in increased expression of VWF mRNA] |
CTD |
PMID:32035215 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wnt3 |
Wnt family member 3 |
decreases expression |
ISO |
Luteolin results in decreased expression of WNT3 protein |
CTD |
PMID:32268164 |
|
NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Luteolin inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]; Luteolin inhibits the reaction [Tunicamycin results in increased expression of XBP1 mRNA alternative form] |
CTD |
PMID:32407927 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
Luteolin inhibits the reaction [Doxorubicin results in increased activity of XDH protein] |
CTD |
PMID:33827303 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Luteolin promotes the reaction [TNFSF10 protein results in increased ubiquitination of and results in increased degradation of and results in decreased expression of XIAP protein] |
CTD |
PMID:16140950 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[luteolin-7-glucoside co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein luteolin-7-glucoside results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31157476 PMID:34165247 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BAX protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] luteolin-7-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of BCL2L1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BID protein alternative form |
CTD |
PMID:34165247 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of CASP3 protein]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP8 protein |
CTD |
PMID:34165247 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP9 protein |
CTD |
PMID:34165247 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:31157476 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNA2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNB1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of CDK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CDK2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of CDKN1A protein |
CTD |
PMID:34165247 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein] luteolin-7-glucoside results in increased activity of ESR1 protein |
CTD |
PMID:31381935 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein] luteolin-7-glucoside results in increased activity of ESR2 protein |
CTD |
PMID:31381935 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of FAS protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein] |
CTD |
PMID:31381935 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein] |
CTD |
PMID:11123379 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of MAPK1 protein 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
luteolin-7-glucoside results in increased cleavage of PARP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] |
CTD |
PMID:34165247 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of RIPK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:31381935 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:11123379 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of TNFRSF1A protein |
CTD |
PMID:34165247 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ADIPOQ protein] |
CTD |
PMID:32044341 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Insr |
insulin receptor |
increases expression |
ISO |
orientin results in increased expression of INSR protein |
CTD |
PMID:32044341 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IRS1 protein] |
CTD |
PMID:32044341 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A protein] |
CTD |
PMID:32044341 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG protein] |
CTD |
PMID:32044341 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARGC1A protein] |
CTD |
PMID:32044341 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
orientin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:32044341 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|